Health Care Law News and Insights

On Monday, Biocon Biologics Limited (Biocon) announced that it will acquire Viatris' rights in biosimilars assets for up to $3.3 billion. Viatris and Biocon previously partnered to bring SEMGLEE to market in the U.S.  SEMGLEE (insulin glargine-yfgn) injection launched last year in the U.S. as the first-ever interchangeable biosimilar approved by the FDA.  Viatris' portfolio also includes...

Read More

During the COVID-19 pandemic, HHS has allowed numerous telehealth flexibilities across Medicare and Medicaid, making it possible for patients to receive care remotely from their homes and enabling states, managed care organizations, and providers to expand access to care. The telehealth landscape looks drastically different now compared with before the...

Read More

The end of 2021 was marked by several significant developments in the wave of litigation that has resulted from the opioid crisis of the last several years. These developments, however, are sufficiently inconsistent that it is difficult to predict where opioid-related lawsuits will land in 2022. On the one hand,...

Read More